SLC5A2 and chronic kidney disease: Emerging therapies, including SGLT2 inhibitors, microbiota-targeted strategies, and novel minimally invasive technologies, offer promise as dual-purpose solutions but require further clinical validation, particularly in advanced CKD cohorts.